Navigation Links
Asthmatx Presents Impact of Bronchial Thermoplasty on Allergy Practices at ACAAI Annual Meeting
Date:11/9/2009

SUNNYVALE, Calif., Nov. 9 /PRNewswire/ -- Asthmatx, Inc. presented the results of a series of studies investigating the effectiveness and safety of bronchial thermoplasty delivered by the Alair® System, and how this new procedure will impact allergy practices, this past weekend in a poster at the 2009 Annual Meeting of the American College of Allergy, Asthma and Immunology (ACAAI), in Miami Beach, Fla.

The poster, titled "Where Could Bronchial Thermoplasty (BT) Fit Into Your Allergy Practice? Lessons Learned from Multiple Bronchial Thermoplasty Clinical Trials," highlighted the clinical results from three randomized clinical trials, which investigated bronchial thermoplasty's effectiveness as a treatment option for patients with severe asthma.

Bronchial thermoplasty is a non-drug procedure developed to treat adults with severe asthma and is designed to provide improved asthma quality of life and control that lasts for at least one year. Bronchial thermoplasty delivered by the Alair System uses thermal energy to reduce the amount of smooth muscle in the lungs, which is associated with airway constriction in asthma patients.

"We have now shown in numerous clinical trials that patients whose severe asthma is uncontrolled by standard medications can now experience clinically significant improvements in their asthma control and their quality of life following treatment with the Alair System," said Glen French, CEO of Asthmatx. "This poster demonstrates that allergists may soon have a new option to consider for their patients with severe asthma."

The poster noted that, while the risks of bronchial thermoplasty include transient worsening of asthma, patients on high doses of inhaled corticosteroids and long-acting bronchodilators with impaired quality of life experience meaningful improvements in their overall asthma status. The poster authors concluded that allergists should consider referring appropriate patient
'/>"/>

SOURCE Asthmatx, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Asthmatx Receives FDA Advisory Panel Recommendation for Approvable with Conditions for Bronchial Thermoplasty with the Alair(R) System for Severe Asthma
2. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
3. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
4. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
5. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
6. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
7. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
8. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
9. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
10. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
11. Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on SLx-4090 at The 16th International Symposium on Drugs Affecting Lipid Metabolism
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... June 18, 2013   Polymer Technology Systems, ... Aegis Health Group to integrate the CardioChek ... programs administered by health systems across the country. ... PTS and distributed through Hanson Medical Systems ... HDL cholesterol, LDL cholesterol, triglycerides, and glucose. ...
(Date:6/17/2013)... 2013  Hanger, Inc. (NYSE:  HGR) today announced the ... its senior secured facilities to an aggregate of up ... credit agreement includes a $200 million revolving credit facility ... credit agreement was comprised of a $100 million revolving ... new facility matures on June 17, 2018, and is ...
(Date:6/17/2013)... , June 17, 2013 BioMed Realty Trust, Inc. ... of directors has declared a second quarter 2013 dividend of ... to an annualized dividend of $0.94 per common share. ... 15, 2013 to stockholders of record at the close of ... Realty Trust BioMed Realty delivers optimal real estate ...
Breaking Medicine Technology:Polymer Technology Systems, Inc. to Provide Point-of-Care Lipid Testing to Aegis Health Group's Hospital Clients 2Polymer Technology Systems, Inc. to Provide Point-of-Care Lipid Testing to Aegis Health Group's Hospital Clients 3Hanger Enters New 5-Year Credit Agreement to Refinance Senior Secured Credit Facilities 2Hanger Enters New 5-Year Credit Agreement to Refinance Senior Secured Credit Facilities 3BioMed Realty Trust Declares Second Quarter 2013 Common Stock Dividend 2BioMed Realty Trust Declares Second Quarter 2013 Common Stock Dividend 3
(Date:6/18/2013)... (PRWEB) June 18, 2013 Exposed Skin Care ... thousands of acne suffers of all ages finally achieve the ... acne treatment products, this new acne clearing system combines the ... and prevent new acne from forming. , After ... believes these products are some of the most effective available ...
(Date:6/18/2013)... 19, 2013 "What if adding one ... could boost your health and well-being? Well, there is ... Sublime Beauty®. "It is called Skin Brushing ." ... became a lost art. Now, people are rediscovering this ... Brushing, and so do certain health conscious people. Sublime ...
(Date:6/18/2013)... PA, June 19, 2013 Recent studies linking ... of bullying-related suicide among young people, led the ... assemble an expert panel to focus on these ... the complex relationship between youth involvement in bullying ... among youth is a significant public health problem, ...
(Date:6/18/2013)... Parker Waichman LLP, a national law ... by dangerous drugs and medical devices, has filed a ... that she was injured by transvaginal mesh ... the U.S. District Court for the Southern District of ... litigation entitled In Re: American Medical Systems, Inc., Pelvic ...
(Date:6/18/2013)... Fla. (PRWEB) June 19, 2013 An ... When Linda Christina Beauregard was diagnosed with breast cancer, ... In her new book, “I Gave Myself Cancer, I ... Life” (published by Balboa Press), Beauregard explains how changing ... cancer. , "Sick people have been made to feel ...
Breaking Medicine News(10 mins):Health News:Exposed Skin Care Review Released by ExposedSkinCareReview.org 2Health News:Exposed Skin Care Review Released by ExposedSkinCareReview.org 3Health News:The Easiest Way to Contribute to Better Health and Well-Being Starting Today and for Under $20, Says Sublime Beauty® 2Health News:Bullying and suicide among youth is a public health problem 2Health News:Boston Scientific and American Medical Systems Named in Transvaginal Mesh Lawsuit Filed by Parker Waichman LLP on Behalf of Arizona Woman 2Health News:Boston Scientific and American Medical Systems Named in Transvaginal Mesh Lawsuit Filed by Parker Waichman LLP on Behalf of Arizona Woman 3Health News:Boston Scientific and American Medical Systems Named in Transvaginal Mesh Lawsuit Filed by Parker Waichman LLP on Behalf of Arizona Woman 4Health News:Cancer Survivor Linda Christina Beauregard Writes New Tell-All Book About Her Alternative Treatment Method 2
... Department of Orthopaedic Surgery at the University of Pittsburgh School of ... Center (UPMC) for Sports Medicine will be installed as the 37th ... Saturday, July 12, 2008, during the Society,s Annual Meeting in Orlando, ... ...
... NASHVILLE, Tenn., July 2 Ambulatory Services of,America, ... Dallas, LLP, its,sixth joint venture to provide outpatient ... joint venture between ASA,s subsidiary, Radiation,Oncology Services of ... Landmark,Radiation Dallas LP. ROSA of North Dallas will ...
... Senate, derailing a critical bipartisan bill that would have ... to physicians who,treat Medicare patients, and made significant improvements ... Last week, Sen. Richard Lugar joined a minority of ... people on Medicare continued,access to their doctors and improved ...
... childbirth as most common reason for hospitalizations, analysis finds ... more than 1.2 million Americans -- roughly equivalent to ... a federal government analysis of hospital admissions and costs ... the most common reason for admission to hospital, and ...
... company with an outstanding track record in the ... technologies, announced availability of the Genomatix Genome Analyzer ... first integrated hardware / software solution for in-depth ... (NGS) devices as provided by Illumina, Roche (454), ...
... simplex out of hiding could bring about a cure, scientists ... Americans are afflicted by breakouts of unsightly cold sores, caused ... finally offering them the possibility of a cure. , Scientists ... herpes simplex 1 slips into dormancy and stays dormant -- ...
Cached Medicine News:Health News:Reknowned Orthopaedic Surgeon to be Installed as President of Sports Medicine Society 2Health News:Reknowned Orthopaedic Surgeon to be Installed as President of Sports Medicine Society 3Health News:Reknowned Orthopaedic Surgeon to be Installed as President of Sports Medicine Society 4Health News:Ambulatory Services of America, Inc. Announces Joint Venture to Operate Radiation Oncology Facility in Dallas, Texas 2Health News:Indiana State Medical Association and AARP Urge Reconsideration of Bill to Protect Seniors' Access to Doctors and Improve Medicare 2Health News:Indiana State Medical Association and AARP Urge Reconsideration of Bill to Protect Seniors' Access to Doctors and Improve Medicare 3Health News:Next generation data analysis for next generation sequencing data 2Health News:New Hope Against the Cold Sore Virus 2Health News:New Hope Against the Cold Sore Virus 3
... establish the patient reportable range and establish ... Linearity is available in five-vial sets with ... 3700 and 4000; Bayer ADVIA 120; Coulter ... 755; Sysmex R-3000, R-3500, R-1000, RAM-1, XE-2100 ...
... CVA for CELL-DYN are assayed linearity control ... and to verify patient reportable range of ... also measure the linear performance of the ... have customized ranges appropriate for each instrument ...
... red blood cell (nRBC) control for evaluating the ... 755 hematology analyzer in its enumeration of the ... LH 750/LH 755. nRBC-Chex for LH is a ... for LH has a 75-day closed-vial stability and ...
... Sickle-Chex is a positive and negative whole ... of Hemoglobin S in solubility tests and ... SICKLEDEX and other manufacturers' solubility kits. ... squeeze dropper vial. The vial dispenses an ...
Medicine Products: